COMPARING PROSTATE SPECIFIC ANTIGEN OUTCOMES AFTER DIFFERENT TYPES OF RADIOTHERAPY MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER HIGHLIGHTS THE IMPORTANCE OF CONTROLLING FOR ESTABLISHED PROGNOSTIC FACTORS-Reference-Cited by-同舟云学术

COMPARING PROSTATE SPECIFIC ANTIGEN OUTCOMES AFTER DIFFERENT TYPES OF RADIOTHERAPY MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER HIGHLIGHTS THE IMPORTANCE OF CONTROLLING FOR ESTABLISHED PROGNOSTIC FACTORS

Published:2000-06 Issue:6 Volume:163 Page:1797-1801
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

D’AMICO ANTHONY V.¹,SCHULTZ DELRAY¹,SCHNEIDER LINDSEY¹,HURWITZ MARK¹,KANTOFF PHILIP W.¹,RICHIE JEROME P.¹

Affiliation:

1. From the Departments of Radiation Oncology and Urology, Brigham and Women’s Hospital, Department of Radiation Oncology, Dana Farber Cancer Institute, Department of Adult Oncology, Lank Center for Genitourinary Oncology, Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts, and Department of Mathematics, University of Millersville, Millersville, Pennsylvania

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference17 articles.

1. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation;Hanks;J Urol,1995

2. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma;Ragde;Cancer,1998

3. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer;Critz;J Clin Oncol,1996

4. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation;Critz;Ca J Sci Am,1998

5. Histologic grading and clinical staging of prostatic carcinoma;Gleason,1977

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2018-10-02

2. Limitations of the National Comprehensive Cancer Network ® (NCCN ® ) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer;Journal of Urology;2017-02

3. Change in the risk stratification of prostate cancer after Slide Review by a uropathologist: the experience of a reference center for the treatment of prostate cancer;International braz j urol;2014-08

4. Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy;Journal of Radiotherapy in Practice;2013-04-23

5. Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity;Prostate Cancer;2012